-
900 million oral hypoglycemic drug Jiangsu pharmaceutical company's first review
Time of Update: 2022-01-12
A few days ago, the official website of the State Food and Drug Administration showed that the voglibose tablets of Suzhou Sinochem Pharmaceutical Industry passed the consistency evaluation, which is the first in China .
-
Northeast Pharmaceutical is married to Jiangxi and commits itself as a "steel straight man"!
Time of Update: 2022-01-12
Therefore, the leaders of state-owned enterprises must reshape their management model, insist on a diversified product portfolio oriented by innovation, brand, and marketing, insist on doing something and not doing something, adjust the way of resource allocation, and realize the company's long-term sustainable development .
-
21 Can pregnant women eat Jinvita?
Time of Update: 2022-01-12
Although this 21 gold vitamin contains folic acid, it is used as a daily nutritional supplement, which is not enough for some pregnant mothers.
-
Hengrui is fully fired!
Time of Update: 2022-01-12
Author: LinglongRecently, Hengrui Pharmaceuticals, the “innovative drug brother”, has frequently issued news: 3 new class 1 drugs have entered the new medical insurance, SHR8554, SHR8008, and SHR8058
-
Innovent's GLP-1R/GCGR dual agonist treatment of type 2 diabetes phase Ib clinical results announced
Time of Update: 2022-01-12
The study is a randomized, double-blind, placebo-controlled Phase Ib clinical study, which aims to evaluate the safety, tolerability and pharmacokinetics of IBI362 multiple dose escalation administration in Chinese type 2 diabetes patients with poor blood glucose control.
-
Youhe Pharmaceutical's Phase I clinical study of anti-4-1BB antibody in Australia completes the first patient administration
Time of Update: 2022-01-12
The main purpose is to evaluate the safety, tolerability and anti-tumor activity of YH004 single-agent and combined anti-PD-1 monoclonal antibody in subjects with advanced solid tumors and relapsed/refractory non-Hodgkin’s lymphoma, and to evaluate YH004’s Pharmacokinetics and immunogenicity .
-
Introduced 15 months of Simcere Pharmaceuticals and submitted a new drug listing application for CDK 4/6 inhibitors
Time of Update: 2022-01-12
According to Simcere’s press release, the first indication applied for Trirazil in China is: preventive use in patients with extensive-stage small cell lung cancer receiving platinum-containing drugs combined with etoposide regimen to reduce chemotherapy-induced The incidence of bone marrow suppression .
-
Sichuan Creed, the only short-acting muscle relaxant in China, won the first imitation!
Time of Update: 2022-01-12
Ammonium has met the requirements for centralized procurement, and the muscle relaxant market will be shuffled; although micuronium has not been squeezed into the TOP10, its sales growth rate in 2021H1 leads all muscle relaxants, reaching 185.
-
CDE releases 3 technical guidelines for anti-coronavirus drugs
Time of Update: 2022-01-12
The original text is as follows:The original text is as follows:The Center for Drug Evaluation of the National Food and Drug Administration on the release of "Technical Guidelines for Non-clinical Pharmacodynamic Research and Evaluation of Anti-coronavirus Chemical Drugs (Trial)" and "Technical Guidelines for Non-clinical Pharmacodynamic Research and Evaluation of Anti-coronavirus Pneumonia Inflammatory Drugs (Trial) ) "Notice of "Technical Guidelines for Non-clinical Research of Novel Coronavirus Neutralizing Antibody Drugs (Trial)" (No.
-
Wanchun Pharmaceutical’s rejection of new drug listing, will Hengrui be implicated in the development of new drugs, will it be a “point of no return”?
Time of Update: 2022-01-12
Can Hengrui break through the “nine deaths and a lifetime” of new drug research and development?Wanchun Pharmaceutical’s core product Punablin was rejected from listing in the United States, plummeting 60%, and its market value fell to less than US$200 million .
-
Hengrui Medicine's PD-1+LAG-3 combination therapy is approved, how is the progress in the clinical LAG-3 field?
Time of Update: 2022-01-12
According to the Insight Global New Drug Database, there are currently as many as 40 antibody drugs targeting LAG-3 under development, including 27 monoclonal antibodies, 12 double antibodies, and 1 fusion protein .
-
The second domestic MASP-2 inhibitor application for clinical application
Time of Update: 2022-01-12
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn December 3, the official website of CDE showed that the clinical application of Omeros's monoclonal antibody OMS721 (arsoplimab) injection targeting MASP-2 has been accepted by the State Food and Drug Administration.
-
Ganli Pharmaceutical declares ultra-long-acting insulin once a week
Time of Update: 2022-01-12
On November 30, Ganli Pharmaceutical announced that its weekly ultra-long-acting insulin weekly preparation GZR4 clinical trial application has been accepted by NMPA (acceptance number: CXSL2101457, the official website has not yet been published) .
-
Azithromycin tablets, a wholly-owned subsidiary of China National Pharmaceutical, passed the consistency evaluation of generic drugs
Time of Update: 2022-01-12
On December 7, China Pharmaceuticals issued an announcement stating that its wholly-owned subsidiary, Tianfangyou, had recently received the Approval Notice of Supplementary Application for Azithromyc
-
The clinical trial application of recombinant human parathyroid hormone for injection, a wholly-owned subsidiary of Buchang Pharmaceuticals, has been accepted
Time of Update: 2022-01-12
On December 1, Buchang Pharmaceutical issued an announcement stating that its wholly-owned subsidiary Luzhou Buchang’s "recombinant human parathyroid hormone (1-84) for injection" clinical trial application was recently accepted by the National Medical Products Administration.
-
Broad-spectrum anti-tumor!
Time of Update: 2022-01-12
BGC0228 replaces the antibody with a polymer target head, and forms a new compound through peptide chain combined with traditional cytotoxic drugs, which achieves precise connection without falling off, and has a smaller molecular weight than ADC drugs, so that it can smoothly penetrate tumor cells and release drugs into tumor cell tissues.
-
Fangsheng Pharmaceutical’s Xuanqijian Bone Tablet was approved and issued by the State Drug Administration as the "Drug Registration Certificate"
Time of Update: 2022-01-12
On December 7, Fangsheng Pharmaceutical issued an announcement stating that it had recently received the "Drug Registration Certificate" approved and issued by the State Food and Drug Administration.
It is used to improve the symptoms of mild to moderate knee osteoarthritis in TCM syndrome, which is the syndrome of musculoskeletal stasis.
-
The first domestic biosimilar drug of smeglutide started clinically from Jiuyuan Gene
Time of Update: 2022-01-12
On November 30th, according to the Insight database, Jiuyuan Gene's smeglutide biosimilar was started clinically, which was the first in China .
-
GZR18, a US subsidiary of Ganli Pharmaceuticals, was approved by the FDA for its clinical trial for the treatment of type 2 diabetes
Time of Update: 2022-01-12
5% of the total population) diabetic patients in the United States in 2018, of which 34.
According to a report released by Grand View Research, the global GLP-1 receptor agonist market share reached US$11.
-
ASKC202, a subsidiary of Aosaikang, obtained the notification of acceptance of clinical trial application
Time of Update: 2022-01-12
ASKC202 tablet is a Class 1 new drug with independent intellectual property rights, and is a potent and highly selective oral small molecule c-MET inhibitor .
Resistance, MET gene amplification occurs in 5%-22% of EGFR inhibitor-resistant non-small cell lung cancer patients .
